




5-Iodotubercidin

1. Description

5-Iodotubercidin is a potent and specific inhibitor of ERK2 (K_i ~0.5 μM) and adenosine kinase (K_i ~30 nM). It has also been reported to abolish the accumulation of AICAR-5'-monophosphate (ZMP) and thus inhibits the activation of AMPK.

2. Product Information

| | |
|---------------------|---|
| 5-Iodotubercidin: | order-no. PKI-ITUB-005 |
| Chemical name: | 4-Amino-5-iodo-7-(beta-D-ribofuranosyl) pyrrolo[2,3-d]-pyrimidine |
| Alternate names: | 5-I-dTu, 7-Deaza-7-iodoadenosine |
| Formula: | C ₁₁ H ₁₃ IN ₄ O ₄ |
| Molecular Weight: | 392.2 g/mol |
| Long Term Storage: | -20°C |
| Purity: | >98% (HPLC) |
| Appearance: | light brown solid |
| Solubility: | Soluble in DMSO |
| Handling: | Protect from light |
| Chemical Structure: | |



3. Product specific literature references:

- *Spychala J, Van den Berghe G (1987) "Adenine nucleotide metabolism in isolated chicken hepatocytes" Biochem. J. 242(2):551-8*
- *Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Di Pasquale G, Carson DA (1993) "New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation" J. Med. Chem. 36(22):3424-30*
- *Kroll K, Decking UK, Dreikorn K, Schrader J (1993) "Rapid turnover of the AMP-adenosine metabolic cycle in the guinea pig heart" Circ Res. 73(5):846-56*
- *Fluckiger-Isler RE, Walter P (1993) "Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin" Biochem. J. 292 (Pt 1):85-91*
- *Massillon D, Stalmans W, van de Werve G, Bollen M (1994) "Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor" Biochem. J. 299 (Pt 1):123-8*
- *Pak MA, Haas HL, Decking UK, Schrader J (1994) "Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices" Neuropharmacology 33(9):1049-53*
- *Parkinson FE, Geiger JD (1996) "Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells" J. Pharmacol. Exp. Ther. 277(3):1397-401*
- *Gu JG, Nath A, Geiger JD (1996) "Characterization of inhibitor-sensitive and -resistant adenosine transporters in cultured human fetal astrocytes" J. Neurochem. 67(3):972-7*
- *Fox T, Coll JT, Xie X, Ford PJ, Germann UA, Porter MD, Pazhanisamy S, Fleming MA, Galullo V, Su MS, Wilson KP (1998) "A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase" Protein Sci. 7(11):2249-55*
- *Kowaluk EA, Kohlhaas KL, Bannon A, Gunther K, Lynch JJ 3rd, Jarvis MF (1999) "Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice" Pharmacol. Biochem. Behav. 63(1):83-9*
- *Abbud W, Habinowski S, Zhang JZ, Kendrew J, Elkairi FS, Kemp BE, Witters LA, Ismail-Beigi F (2000) "Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport Arch. Biochem. Biophys. 380(2):347-52*
- *Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, Busse R (2003) "AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets" Thromb Haemost. 90(5):863-71*